imatinib has been researched along with Osteosarcoma in 1 studies
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X | 1 |
| Liu, L | 1 |
| Liu, P | 1 |
| Chen, Y | 1 |
| Lin, D | 1 |
| Yan, H | 1 |
| Yan, Q | 1 |
| Wang, Y | 1 |
| Qiu, Y | 1 |
| Fang, B | 1 |
| Huang, H | 1 |
| Qian, J | 1 |
| Zhao, Y | 1 |
| Du, Z | 1 |
| Zhang, Q | 1 |
| Li, X | 1 |
| Zheng, X | 1 |
| Liu, Z | 1 |
1 other study available for imatinib and Osteosarcoma
| Article | Year |
|---|---|
Discovery of Potent and Orally Bioavailable Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for the Treatment of Osteosarcoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Osteosarcoma; Receptor Protein-Tyrosine Kinases; Rece | 2022 |